Last reviewed · How we verify
Cortone (CORTISONE ACETATE)
At a glance
| Generic name | CORTISONE ACETATE |
|---|---|
| Sponsor | Merck |
| Drug class | alpha-Adrenergic Agonist [EPC] |
| Target | Corticosteroid-binding globulin |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1950 |
Approved indications
- Acne vulgaris
- Acquired thrombocytopenia
- Acute lymphoid leukemia
- Adrenal cortical hypofunction
- Adrenogenital disorder
- Allergic conjunctivitis
- Allergic rhinitis
- Angioedema
- Ankylosing spondylitis
- Aphthous ulcer of mouth
- Articular gout
- Aspiration pneumonitis
- Asthma
- Atopic dermatitis
- Autoimmune disease
- Autoimmune hemolytic anemia
- Bacterial keratitis
- Berylliosis
- Blepharoconjunctivitis
- Bursitis
Common side effects
Drug interactions
- aripiprazole
- quetiapine
- rifabutin
- rifampicin
- risperidone
- warfarin
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Conservative Treatment of Trigger Finger (NA)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL) (PHASE1)
- Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (PHASE3)
- Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer (PHASE1,PHASE2)
- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cortone CI brief — competitive landscape report
- Cortone updates RSS · CI watch RSS